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ABSTRACT 
Enteric disease and immune challenge are processes that have detrimental effects on 
growth performance of young swine.  The current study tested the hypothesis 
salmonellae-induced enteric disease would perturb the endocrine growth axis in a serovar 
dependent fashion. Specifically, we evaluated effects of Salmonella enterica serovar 
Typhimurium (Typhimurium) and serovar Choleraesuis (Choleraesuis) on critical 
regulatory components of growth in young swine. Weaned pigs were housed 2 per pen 
with ad libitum access to feed and water in a 14 d experiment.  Pigs were then repeatedly 
fed either 108 CFU Choleraesuis or 108 Typhimurium in dough balls, with control pigs 
receiving dough without bacteria.  Bacteria were re-fed twice weekly.  Rectal 
temperatures were monitored daily from d 0 to7 and ADFI was measured through d 14. 
Pigs were weighed and samples of serum were obtained for circulating IGF-I on days 0, 
7, and 14.  At the conclusion of the study, samples of semitendinosus muscle and liver 
were obtained and subsequently assayed for IGF-I, IGFBP-3, and IGFBP-5 mRNA.  
Rectal temperatures were elevated in pigs given Choleraesuis pigs from d 2 through d 7 
(P < 0.05) when compared to control pigs and pigs fed Typhimurium. Pigs receiving 
Choleraesuis had substantially decreased feed intake on days 2, 3, 4, 7, 8, 9, and 10 (P < 
0.01), with a trend for reduction on d 5 (P = .08), and they experienced an approximate 
25% reduction in BW compared to control and Typhimurium pigs by the conclusion of 
the study. Pigs given Choleraesuis also experienced marked reductions in circulating 
IGF-I on d 7 (P < 0.01 vs. control and Typhimurium) with reductions of lesser magnitude 
on d 14 (P = 0.07 vs. control and P < 0.05 vs. Typhimurium). Treatment tended to affect 
liver IGFBP-3 mRNA (P = 0.08), where expression tended to be elevated in 
Typhimurium and Choleraesuis pigs.  In contrast, IGFBP-3 mRNA relative abundance 
was increased (P < 0.03) in pigs given Typhimurium versus control pigs. Muscle IGF-I 
mRNA was reduced in Choleraesuis pigs compared to control and Typhimurium (P < 
0.05). Treatment tended to affect muscle IGFBP-3 mRNA (P = 0.10), where Choleraesuis 
had numerically less relative abundance than controls.  Oral inoculation of growing pigs 
with Choleraesuis disrupted feed intake and BW gain, and this was accompanied by 
decreases in circulating IGF-I and reduced muscle expression of mRNA for  IGF-I and 
IGFBP-3.
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Chapter 1 
A Review of Critical Components of the Somatotropic Growth Axis and Concepts of 
Disease-Associated Growth Retardation 
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ABSTRACT 
Enteric disease and immune challenge are processes that are accepted as 
contributors to diminished growth in animals, including swine.  Studies conducted with 
numerous animal models of infection suggest that disease challenge results in activation 
of the immune system and redirection of dietary nutrients from normal growth and 
development towards supportive functions used to enhance the immune response.  
Research in the field of salmonellosis in swine has resulted in further data to support this 
idea.  In the United States,  two serovars of Salmonella enterica namely Salmonella 
enterica serovar Typhimurium (Typhimurium) and serovar Choleraesuis (Choleraesuis) 
account for nearly all cases of salmonellosis in swine. Each of these serovars has 
differing biological effects on the pig.  In swine, each serovar invokes specific responses, 
with Typhimurium producing mainly self-limiting enteritis and Choleraesuis resulting in 
more serious and occasionally fatal septicemia.  In light of the more localized enteric 
nature of physiologic responses of swine to Typhimurium and the apparent tendency of 
Choleraesuis to result in symptoms more in line with systemic disease, it is reasonable to 
assume that these serovars may have divergent effects on fundamental components 
regulating growth in young swine. This report aims to review published information on 
mechanisms of Typhimurium- and Choleraesuis-induced reductions in growth of  swine 
and, for additional context, to more broadly consider other established enteric models of 
disease in animals and key components of regulatory pathways of animal growth. 
KEYWORDS: Enteric Disease, Growth, Swine, Salmonella, Salmonella Typhimurium, 
Salmonella Choleraesuis 
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 INTRODUCTION 
One of the hallmarks of the pathophysiology of enteric disease is reduced growth 
performance.  This reduction in growth is associated with changes in both the endocrine 
and local somatotropic growth axis (Jenkins et al., 2004). Components of this axis 
include both central neuroendocrine and local autocrine and paracrine factors. Among 
these factors are: growth hormone (GH), the growth hormone receptor (GHR), the growth 
hormone binding proteins (GHBPs), insulin-like growth factors I and II (IGF-I and IGF-
II), as well as the IGF receptors and the six known IGF binding proteins (IGFBPs) 
(Frago, 2005).   The neuroendocrine and the immune systems interact to coordinate 
physiological responses to infection and inflammation.  These adaptive responses include 
the induction of inflammatory mediators and fever, reduced feed intake with diminished 
growth performance, and development of a regulated and specific immune response to 
the pathogen.  It is thought that this bi-directional communication may coordinate 
appropriate physiological responses in such a way that nonessential functions (e.g. 
growth) can be suspended temporarily while the host mounts a response that will return it 
to homeostasis (Balaji et al., 2000).  The detrimental effect of disease and immunological 
stress on growth rate and efficiency of gain in food animals is of considerable economic 
importance (Spurlock et al., 1997) as it has been shown that immunological stress can 
reduce growth rate and feed efficiency from 10 to 25% (Webel et al., 1997; Fraser et al., 
2007).  The emerging view is that the reduction in feed intake and growth observed in 
disease or immunologically challenged pigs is the result of increased cytokine secretion 
(Webel et al., 1997) as it is established that inflammatory cytokines are associated with 
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decreased voluntary food intake, increase resting energy expenditure and body 
temperature, and altered nutrient metabolism (Dritz et al., 1996).  Cytokines are small 
nonstructural proteins, or glycoproteins that serve as chemical messengers between cells 
and are mainly involved in regulation of the immune response. However, recent evidence 
has shown that they are involved in different physiological processes such as cell growth 
and differentiation, tissue repair and remodeling, and aging (Zoico et al., 2002).  
Cytokines can also influence different functions of skeletal muscle cells and are part of 
the normal adaptive response of the tissue to physical stress.  They play an important role 
not only in muscle homeostasis, but also in disease pathogenesis (Zoico et al., 2002).  
Pathological conditions, such as inflammatory disease, can result in a decrease in lean 
body mass.  Elevated levels of systemic cytokines, such as IL-1, IL-6, and TNF-α are 
associated with these inflammatory conditions (Johnson et al., 2005) and have been 
shown to decrease circulating and tissue levels of important anabolic hormones (Frost et 
al., 2002) as well as invoke other immune modulators such as glucocortocoids, 
prostaglandins, and catecholamines, all of which may affect cell metabolism and growth 
(Spurlock et al., 1997).  Experimental findings with purified lipopolysaccharide (LPS), 
Salmonella enterica serovar Typhimurium (Typhimurium) and serovar Choleraesuis 
(Choleraesuis) have supported the hypothesis of inflammatory processes and negative 
effects on growth.  This report aims to review current literature on the effects of immune 
challenge in various models, including oral inoculation with Typhimurium and 
Choleraesuis; to review the processes that may be involved in the characteristic decrease 
in growth performance that follows immune challenge; and to review the processes 
involved in normal growth and development in various animal models. 
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REGULATION OF GROWTH 
 Growth Hormone.  Physiological processes such as growth are carefully 
orchestrated and controlled by complex interactions among a multiplicity of hormones 
and growth factors (Boyd, 1989).  These factors can modulate growth both in an 
endocrine and local manner. Growth hormone (GH) is produced primarily, or almost 
exclusively, by somatotrophs of the anterior pituitary, and its synthesis and secretion is 
under the control of the hypothalamus via two hypothalamic factors: the stimulating 
factor known as growth hormone releasing hormone (GHRH) and the inhibiting factor 
being somatostatin (Frago, 2005).   It is now firmly established  that GH plays a key role 
in the regulation of mammalian growth (Peng et al., 1996) and is a major regulator of 
metabolism (Breier et al., 1999).    
IGF-I.  The effects of GH are mediated through insulin-like growth factors 
namely insulin-like growth factor I (IGF-I) and  insulin-like growth factor II (IGF-II) 
(Oksbjerg et al., 2004) with both IGFs and their receptors being found in a variety of 
tissues and cell types, as well as in plasma and other biological fluids (Peng et al., 1996; 
Silha, 2005).  Initially, the dogmatic view was that GH secreted from the pituitary gland 
acted on the liver where it stimulated specific receptors and initiated the synthesis of a 
compound, later known as IGF-I from hepatic tissues.  In many mammals, including 
swine, the majority of IGF-I found in circulation is thought to be produced by hepatic 
tissue  (Breier et al., 1999; Fan et al., 1994; Florini et al., 1996; Oksbjerg et al., 2004; 
Peng et al., 1996). However, the liver is not the only source. Further research has shown 
that other tissues, such as skeletal muscle, are intrinsically capable of producing their 
own IGF-I (Breier et al., 1999; Fan et al., 1994; Florini et al., 1996; Oksbjerg et al., 
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2004; Peng et al., 1996) and therefore seem to utilize both circulating as well as locally 
synthesized IGF-I in an autocrine/paracrine fashion (Adamo, 2005).  This concept is 
important, as it has been documented that approximately two thirds of growth to normal 
size that occurs postnatally is attributed to the autocrine/paracrine production and 
utilization of IGF-I (Novakofski, 1993).  Evidence for this concept originates from 
research conducted in mouse models, in which genes for hepatic IGF-I production are 
eliminated.  Thus, these mice experience drastic reductions in circulating IGF-I, but still 
grow to normal body size (Sjogren et al., 1999; Yakar et al., 1999) and provide further 
strength to support the importance of locally produced IGF-I in postnatal growth and 
development.  Regardless of the source, it is accepted that IGF-I is a well documented 
and important regulator of growth and development, particularly of skeletal muscle 
(Fernandez, 2005; Florini et al., 1996; Sheffield-Moore et al., 2004). IGF-I also is a 
potent agent that affects the proliferation of a wide variety of cell types (Frago, 2005; 
Hathaway et al., 2003).  In addition, IGF-I is recognized to influence various aspects of 
carbohydrate, lipid and protein metabolism (Fan et al., 1994), and is considered a 
dominant factor in the postnatal growth and hypertrophy of skeletal muscle cells.  
Through actions such as enhancing satellite cell proliferation in muscle cells, DNA 
content related to postnatal myofiber hypertrophy is increased (Oksbjerg et al., 2004) 
with this amount of available DNA related to the amount of protein synthesis that occurs 
in muscle fibers postnatally (Novakofski, 1993).  Indeed it has been shown that addition 
of IGF-I to myotube cultures of several cell lines and primary satellite cells increases the 
rate of protein synthesis and decreases the rate of protein degradation (Oksbjerg et al., 
2004) with the decreases in degradation thought to be related to the ability of IGF-I to 
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inhibit actions of the ubiquitin-proteasome system (Johnson et al., 2005). Collectively, 
IGF-I has been found to contribute to the increases seen in muscle size as growth occurs,  
and has been shown to have effects on myoblast proliferation and stimulation of 
differentiation, as well as the stimulation of nutrient uptake and inhibition of proteolysis 
(Novakofski, 1993).  
The mechanisms behind how IGF-I is regulated, both in circulation and local 
production are still under investigation, however it is accepted that IGF-I secretion from 
the liver, being the endocrine form found in plasma, is mostly dependent on the amount 
of GH secreted from the anterior pituitary (Adamo, 2005), with a negative feedback 
relationship occurring between IGF-I and GH, in which increasing amounts of IGF-I in 
circulation from the liver lead to decreasing amounts of GH release from the anterior 
pituitary (Scanes, 1995).  It has also been found that the rate of GH secretion is related to 
nutrition, and that the amount of IGF-I produced by the liver is dependent on the number 
of receptors for GH found on hepatic tissue (Breier et al., 1999; Scanes, 1995; Thissen, 
2005).  IGF-I production at tissues other than hepatic tissue, specifically skeletal muscle, 
is also related to GH secretion (Breier et al., 1999; Florini et al., 1996; Scanes, 1995; 
Sheffield-Moore et al., 2004) but there has been some controversy as to the magnitude of 
the role of GH.  For example, cultured myoblasts release IGFs intrinsically, but the 
relationship to GH treatment remains unclear, as there are conflicting studies examining 
the relationship between GH treatment and expression of IGFs.  However, it remains a 
central principle that IGF expression in other tissues, including skeletal muscle, can occur 
both in the presence of GH and in its absence, although fundamental details of the 
regulation are yet to be clearly defined (Fernandez, 2005).  Nevertheless, it is clear that a 
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relationship exists between GH and IGF-I. Overall the currently accepted view is that 
IGF-I, whether in circulation or intrinsically produced, is a potent mediator of GH and a 
necessary regulatory factor in the development of skeletal muscle and other tissues within 
the body. 
IGFBPs.  IGF’s found in plasma and extracellular fluids exist predominantly in a 
complex with insulin-like growth factor binding proteins (IGFBPs) which control the 
bioavailability of the IGFs, and modulate their binding to target cell receptors.  These 
IGFBP’s are responsible for harboring IGF-I in circulation, thereby expanding its half-
life and modulating its action on certain receptors for various tissues in the body (Florini 
et al., 1996; Peng et al., 1996; Silha, 2005).  Outside of circulation, most target tissues 
also express IGFBPs as well as receptors for them, where they further regulate the local 
actions of the IGFs (Fernandez, 2005).  In addition, all six IGFBPs found in circulation 
are also produced by individual tissues in a cell-type specific combination, with IGFBPs -
2, -4, -5, and -6, found to be produced by skeletal muscle (Fernandez, 2005).  Whereas 
this review will not cover the discovery and subsequently identified functions of each of 
the six known binding proteins in detail, focus will be on IGF binding protein 3 (IGFBP-
3) and IGF binding protein 5 (IGFBP-5), because they are two binding proteins thought 
to play the largest role in the growth and development of porcine skeletal muscle; to 
mediate growth effects of IGF-I; and, therefore, to be subject to modulation of growth by 
enteric disease.  Moreover, it has been well documented that these two binding proteins 
are responsible for sequestering more than 90% of IGF-I in circulation (Thissen, 2005) 
and that they form a ternary complex with an acid labile sub-unit (ALS) (Sandhu, 2005; 
Scanes, 1995; Silha, 2005; Thissen, 2005). 
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IGFBP-3.  IGFBP-3 is the most abundant IGFBP in circulation (Silha, 2005) and 
is the major circulating carrier of IGF-I in postnatal life (Spagnoli, 2005).  It is also a key 
component of the ternary complex made up of IGF-I, IGFBP-3, and ALS (Roberts, 2005; 
Silha, 2005).  It is heavily expressed in hepatic tissues, but additionally is synthesized  in 
other tissues including skin, skeletal muscle, reproductive organs, bone, and endothelium 
and has a central role in the regulation of IGF transport to tissues (Silha, 2005). IGFBP-3 
sequesters between 75 to 90% of IGF-I in circulation (Sandhu, 2005), and like most other 
IGFBPs, the function of IGFBP-3 is to prolong the half life of IGF-I, act as a transport 
protein across the capillary barrier of tissues, and modulate presentation of IGF-I to its 
receptors on these tissues (Spagnoli, 2005).  Interestingly though, IGFBP-3 also has a 
broad range of functions that are independent of its binding to IGF-I, including the 
control of cell proliferation, controlling glucose uptake, and even inducing or enhancing 
cell apoptosis (Spagnoli, 2005).  Furthermore, a role for IGFBP-3 in various types of 
cancers, in to tumor suppression and in anti-apoptotic effects on various cell types has 
been proposed, although understanding of these functions continues to emerge (Lee et al., 
2002b). 
In serum, IGFBP-3 concentrations are tightly regulated by a number of factors, 
but most importantly by the rate of its hepatic synthesis in the liver, a process which is 
substantially linked to the amount of IGF-I produced by the liver itself, and which in turn 
is related to the amount of GH released (Scanes, 1995; Silha, 2005).  Other important 
factors for the regulation of serum IGFBP-3 include nutrient and dietary intake, as it has 
been shown that hepatic IGFBP-3 concentrations in serum become reduced during 
protein restriction or malnutrition (Silha, 2005) and that this effect may be mediated 
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primarily by increased concentrations of insulin, glucose, and amino acids in circulation 
(Thissen, 2005).  Although chronic dietary restriction can result in decreasing levels of 
IGFBP-3 in circulation (Lee et al., 2002a; Thissen, 2005), these changes are also often 
paralleled in hepatic tissue, where decreasing levels of IGFBP-3 mRNA are expressed 
(Thissen, 2005).  Changes in the amount of IGFBP-3 in other tissues, such as skeletal 
muscle for example, have been more difficult to quantify as the cellular mechanisms 
behind IGFBP-3 regulation have not been fully elucidated and remain largely 
undetermined (Granata et al., 2004; Takaoka et al., 2004).  Thus, IGFBP-3 is an 
important mediator of the biological actions of IGF-I, but has several other important 
functions independent of those mediated by binding to IGF-I, including participation and 
regulation of processes such as cell growth, differentiation, and proliferation. 
IGFBP-5.  Like IGFBP-3, IGFBP-5 is capable of forming a ternary complex with 
IGF-I and is in part responsible for binding and mediating its effects, with approximately 
58% of it present in circulation in conjunction with IGF-I and ALS (Silha, 2005; Thissen, 
2005).  IGFBP-5 also contributes to homeostasis in bone, ovary, kidney and skeletal 
muscle (Silha, 2005).  It is intrinsically produced and secreted by cultured muscle cells 
(Fernandez, 2005), the functions and regulatory pathways of which are currently under 
study.  In addition, IGFBP-5 appears to be associated with the differentiation of cultured 
muscle cells, and it may play a role in myogenesis (Florini et al., 1996).  Much like all 
other known IGFBPs, it appears to be tightly regulated by nutrition (Thissen, 2005).  
IGFBP-5 is also protected via IGF-I that it is bound to, in addition to the stimulation of its 
transcription by IGF-I and GH (Silha, 2005).  It has been suggested  that the regulation of 
expression of IGFBP-5, at least in proliferating porcine satellite cells, was also affected 
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by transforming growth factor β1 (TGFβ1), as IGFBP-5 mRNA expression was increased 
by 50%, suggesting another possible pathway for the control of expression (Oksbjerg et 
al., 2004). However, it is important to note that the precise functions and nutritionally-
regulated mechanisms for IGFBP-5 expression are largely unknown (Thissen, 2005).  
Much like IGFBP-3 however, IGFBP-5 has also participates in various biological 
processes independent of binding or interacting with IGF-I.  Specifically, IGFBP-5 plays 
a major role in bone growth (Franchimont et al., 1997; Schneider et al., 2002) and 
participates to varying degrees in mammary gland involution, both follicular growth and 
atresia, in kidney development and function, and similar to IGFBP-3, in various types of 
cancers (Schneider et al., 2002).  
CYTOKINE MEDIATED EFFECTS ON COMPONENTS OF THE 
SOMATOTROPIC GROWTH AXIS 
 Reductions in body weight gain in growing pigs in response to enteric challenge 
with Typhimurium or Choleraesuis appear to be largely related to disease-associated 
depression in feed intake.  Of particular importance to research models is the view that 
cytokines produce periods of inappetence and lethargy are associated with decreased feed 
intake and overall poor nutrient utilization (Johnson, 1997; Kelley, 1993; Spurlock et al., 
1997).  These reviews probed the hypothesis that certain inflammatory cytokines, 
generated in response to an enteric pathogen by the host immune system, including TNF-
α, IL-1, and IL-6, may be part of the underlying cause and that interactions between the 
immune system and disease challenge may be responsible for these negative effects.  
Therefore, certain components of the somatotropic growth axis known to regulate normal 
growth and development, including GH, IGF-I, IGFBP-3, and IGFBP-5, have been 
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implicated in disease challenge models to further clarify the interaction between immune 
challenge and growth. 
 EFFECTS ON GH AND GHR.  It is accepted that GH plays a key role in the 
regulation of mammalian growth (Peng et al., 1996), therefore the study of the effects 
that a disease challenge presents on GH is relevant.  Normal, pulsatile secretion of GH 
from somatotrophs in the anterior pituitary is an important regulator of normal growth 
and development (Frago, 2005). The relationship between immune challenge, depressed 
growth and GH is likely being multifaceted (Spurlock et al., 1997). 
Although results of disease models, such as injection of LPS, have documented 
variable effects on GH secretion in domestic farm animals (increased in sheep: Coleman 
et al., 1993; transiently increased in pigs: Wright et al., 2000; decreased in cattle: 
Elsasser et al., 1988, 1995), relatively few studies have evaluated secretion of GH in 
response to bona fide disease challenge. Weaned pigs challenged orally with 109 CFU of 
Typhimurium experienced intermittent elevations of GH in serum compared with their 
control group counterparts (Balaji et al., 2000).  The transient elevations in GH in that 
study may have been associated with decreased nutrient intake and the accompanying 
decrease in circulating IGF-I.   
Nutritional status plays a major role in determining circulating GH concentrations 
as well as the negative effects that inadequate nutrition can have on the GH receptor in 
hepatic tissue, which has been established as being a critical link in IGF-I synthesis and, 
consequently, growth (Breier et al., 1999).  The role of cytokines, as they have been 
shown to negatively affect feed intake (Dantzer, 1993; Johnson, 1997), may therefore 
indirectly alter GH.  Decreased feed intake can alter not only the amount and pattern of 
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GH secretion, but it has also been shown that food deprivation can decrease the number 
of GH receptors (GHR) on hepatic tissue as well as downstream receptor signaling.  
Amounts of GHR mRNA in liver tissue of steers that had either been food deprived and 
allowed a diet of water only were compared to a group of steers allowed free access to 
water, grass, and grain supplementation (Wang et al., 2003).  Analysis of liver tissues 
showed decreased GHR mRNA in the hepatic tissues of the food deprived steers. 
Paralleling these results, pig hepatocyte cultures were placed media containing an array 
of amino acids and glucose, or simply in culture with amino acids only (Brameld et al., 
1999).  Results showed that hepatocytes in culture free of glucose had substantially less 
GHR expression than those exposed to glucose, again supporting the theory that nutrition, 
possibly glucose in particular, plays an important role in GHR expression and function.  
Thus, nutrient intake in response to disease challenge may play a key role in mediating 
the effects of GH partially through receptor expression in tissues, especially the liver. It 
also appears that inflammatory cytokine activity during an immune challenge, such as in 
the case of LPS or Salmonella infection, can affect nutritional status by affecting feed 
intake as part of the immune response, as well as alter nutrient utilization by shifting 
nutrients towards supporting immune function and away from growth promotion. 
Although it has been established that nutrition plays a key role in mediating the 
effects of GH as well as being important for normal receptor signaling function, ongoing 
research has begun to elucidate the direct effects that inflammatory cytokines may have 
on GH as well as its receptor.  An emerging parallel dogma is that nutrition may not be 
the only way in which GHRs are regulated, and that known inflammatory cytokines may 
have direct effects on the secretion of GH and furthermore effect GHR’s in hepatic tissue.  
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It has been suggested that GH secretion may be directly affected by IL-1β by affecting 
the pulsatile release of GH as well as negatively affecting GH-releasing hormone 
(GHRH) secretion while upregulating the release of somatostatin, a known inhibitor of 
GH release (Spurlock et al., 1997).  This view is significant as it has been established that 
LPS, as well as salmonellae infections, lead to expression of IL-1, and a link between IL-
1 and GH could explain a basis for decreased growth in swine.  Another known 
inflammatory cytokine IL-6, can affect GHR post-receptor signaling in rat hepatic tissue 
through inhibition of the JAK/STAT dependent signaling pathway at different levels 
(Wang et al., 2002a).  In addition, TNF-α has also been implicated in reduced expression 
of liver GHR mRNA (Wang et al., 2002b).  
EFFECTS ON IGF-I.  It has been widely accepted that the regulation of IGF-I 
production both by hepatic as well as in non-hepatic tissues is largely related to GH 
secretion (Adamo, 2005) as well as nutrition (Adamo, 2005; Breier et al., 1999), but the 
effect of cytokines induced by an immune challenge have also been implicated in playing 
a role as well, both on circulating as well as tissue levels of IGF-I (Frost et al., 2002).   
In circulation, IGF-I is an important product of the liver, however, recent 
evidence suggests that not all of this IGF-I in circulation is a result of hepatic production, 
and that local production of IGF-I by non-hepatic tissues plays an important role is well, 
and is likely to contribute substantially to the final biologically active pool of IGF-I 
(Frost et al., 2004).  It is thought that inflammatory mediators, such as TNF-α, IL-1, or 
IL-6 may somehow affect production or regulatory pathways involved in IGF-I mediating 
the effects of GH.  In particular, TNF-α may be major player in down regulating the 
effects of IGF-I.  Cultured human myoblasts treated with TNF-α experienced reduced 
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ability for myoblasts to conduct protein synthesis for at least 48 hrs, but with no affect on 
the ability of IGF-I to bind to these cells, suggesting that TNF-α may affect some aspect 
of the IGF-I signal transduction pathway (Frost et al., 1997).  Incubation of TNF-α with 
C2C12 myoblasts resulted in progressive declines in total IGF-I mRNA levels through 10 
hrs, suggesting that TNF-α may also hamper essential pathways for local IGF-I 
production in muscle cells (Fernandez-Celemin et al., 2002). More recently,  it was 
shown that TNF-α induced a state of receptor resistance in C2C12 myoblasts by affecting 
the docking proteins IRS-1 and IRS-2 that are critical for IGF-I to bind to its receptor 
(Broussard et al., 2003).  In a model of Porcine Reproductive and Respiratory Virus 
(PRRSV) disease in young pigs, systemic elevations of IL-1β and IL-6 that were 
negatively correlated with parameters such as feed intake, body weight gain, and protein 
accretion in muscles such as the biceps femoris, providing further evidence for the 
relationship between cytokines and their effects on feed intake as well as hampering the 
process of normal skeletal muscle growth and development (Escobar et al., 2004).  These 
studies taken together suggest that receptor resistance, coupled with decreased protein 
synthesis, decreased feed intake,  and inhibition of local IGF-I production may be an 
explanation for the lack of muscle growth seen in animals under disease challenge, and 
suggest a mechanism for the inability of IGF-I to modulate the actions of GH. 
EFFECTS ON IGFBP-3.    IGFBP-3 appears to be potently regulated by nutrition 
as well as by the amount of IGF-I produced by the liver and the amount of GH secreted, 
which may be affected by known inflammatory cytokines IL-6 and TNF-α.  It is accepted 
that IGFBP-3 regulation is directly related to feed intake as a result of the interaction 
between cytokines, feed intake, and nutritional effects on the IGF/GH axis in the liver.  
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However, knowledge about the direct affects that inflammatory cytokines may play on 
this important mediator of IGF-I function is generally lacking. 
Circulating IGFBP-3 concentrations are reduced under conditions of restricted 
energy or feed intake (Lee et al., 2002a).  Pigs infected with 1010 CFU Typhimurium 
showed reductions in IGFBP-3 serum at 24, 48, 96, and 168 hours after infection (Jenkins 
et al., 2004). Since IGFBP-3 is established as a primary sequestering agent for IGF-I, 
reduced concentrations of IGFBP-3 may enhance the availability of the remaining IGF-I 
to tissues (Breier et al., 1999).  Although data concerning the effects that inflammatory 
cytokines on IGFBP-3 are generally lacking, a role for IL-6 on IGFBP-3 has been 
suggested.  Mice overexpressing IL-6 (NSE/hIL-6) showed a marked decrease in the 
amount of IGFBP-3 in circulation compared to their wild-type counterparts.  Transgenic 
mice also showed marked increases in the proteolytic cleavage of IGFBP-3 in circulation, 
further showing that IL-6 may affect not only IGFBP-3 production, but that it may also 
play an important role in the degradation of existing IGFBP-3 (DeBenedetti et al., 2001).  
In that same study, injections of exogenous recombinant human IL-6 to CB6F1 mice 
(non-transgenic counterparts of the same strain as the NSE/hIL6 mice) resulted in 
significant decreases in IGFBP-3 in circulation 24 hours after treatment as well.  In 
addition, human patients with systemic juvenile idiopathic arthritis followed the same 
trend when compared to age matched controls, with decreased IGFBP-3 in serum as well 
as increased proteolysis of IGFBP-3 in the presence of high levels of IL-6, a 
distinguishing characteristic of this disease  
Another inflammatory cytokine, TNF-α, has also been implicated in its ability to 
inhibit patters of growth in human muscle cells.  Treatment of human myoblast cell 
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cultures with TNF-α inhibited IGFBP-3 secretion in a dose dependent manner, thereby 
blocking the ability for IGFBP-3 to induce myoblast differentiation and having further 
ramifications on skeletal muscle development and growth (Foulstone et al., 2003).  
Collectively, evidence for the negative effects cytokines may have on IGFBP-3 is 
mounting, and further research may help advance understanding of the interactions that 
occur. 
EFFECTS ON IGFBP-5.  The most conserved IGFBP across species, IGFBP-5, 
plays an important role in several biological processes including bone, ovary, mammary 
gland, and kidney physiology (Schneider et al., 2002) and is an important component of a 
ternary complex with ALS and IGF-I (Silha, 2005; Thissen, 2005).  It is also the 
predominant IGFBP synthesized by skeletal muscle (Lang et al., 2006).  However, data 
concerning the direct effects that inflammatory mediators may have on IGFBP-5 function 
or expression are lacking.  It is known that inflammatory cytokines IL-1 and IL-6 
increase IGFBP-5 mRNA in bone cells (Franchimont et al., 1997; Sunic et al., 1998) but 
the effects of catabolic insult on IGFBP-5 in other tissues, particularly on skeletal muscle, 
that can occur as a result of sepsis remains relatively undetermined.  Intraperitoneal 
injection of LPS in rats reduced IGFBP-5 mRNA concentrations in gastrocnemius muscle 
by 40-45% between 4-12 hrs after LPS, and the relationship was found to be dose 
dependent at the 8 h timepoint (Lang et al., 2006).  Cecal ligation and puncture also 
resulted in decreasd IGFBP-5 mRNA in gastrocnemius muscle again and increased serum 
levels of TNF-α (Lang et al., 2006).  In that same study, it was also found that continuous 
infusion of TNF-α resulted in significant decreases in IGFBP-5 mRNA as well, but these 
results were counteracted when rats were pretreated with TNFBP, a protein responsible for 
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binding TNF-α. Thus, increased concentrations of TNF-α appear to be associated with 
decreased IGFBP-5 expression in skeletal muscle.  These data suggest that inflammatory 
challenge in a septic models has negative effects on IGFBP-5 production, and can thereby 
hamper IGFBP-5, an important protein responsible for normal muscle growth and 
development.   
CONCLUSION 
Inflammatory cytokines produced by an organism’s immune system in response 
to infectious challenge can have dramatic effects on the central nervous system, alter 
behavior, and alter dominant components and control points of the somatotropic growth 
axis.  It is these effects on behavior, nutrient deposition, and interactions with known 
promoters of growth and development, both in circulation and at local levels, that appear 
to be a driving force behind the deleterious effects of disease pathogenesis on growth and 
development.  
18 
 
REFERENCES 
 
Adamo ML (2005). Overview and Molecular Aspects of the Insulin-Like Growth Factor 
System. In: Houston MS, Holly JMP and Feldman EL (eds) IGF and nutrition in 
health and disease. Totowa, N.J: Humana Press, pp. 1-22. 
Balaji R, Wright KJ, Hill CM, Dritz SS, Knoppel EL and Minton JE (2000). Acute phase 
responses of pigs challenged orally with Salmonella typhimurium. J. Anim. Sci. 
78: 1885-1891. 
Boyd DR and Bauman DE (1989). Mechanisms of Action for Somatotropin in Growth. 
In: Campion DR, Hausman GJ and Martin RJ (eds) Animal Growth Regulation. 
New York: Plenum Press, pp. 257-293. 
Brameld JM, Gilmour RS and Buttery PJ (1999). Glucose and amino acids interact with 
hormones to control expression of insulin-like growth factor-I and growth 
hormone receptor mRNA in cultured pig hepatocytes. J .Nutr. 129: 1298-1306. 
Breier BH (1999). Regulation of protein and energy metabolism by the somatotropic axis. 
Domest. Anim. Endocrinol. 17: 209-218. 
Broussard SR, McCusker RH, Novakofski JE, Strle K, Shen WH, Johnson RW, Freund 
GG, Dantzer R and Kelley KW (2003). Cytokine-hormone interactions: tumor 
necrosis factor alpha impairs biologic activity and downstream activation signals 
of the insulin-like growth factor I receptor in myoblasts. Endocrinology 144: 
2988-2996. 
Dantzer R (1993). Cytokines and Sickness Behavior. In: Husband AJ (eds) 
Psychoimmunology CNS-immune interactions. Boca Raton: CRC Press, pp. 1-16. 
DeBenedetti F., Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, 
Garrone S, Barreca A and Martini A (2001). Effect of IL-6 on IGF binding 
protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile 
idiopathic arthritis. Endocrinology 142: 4818-4826. 
Dritz SS, Owen KQ, Goodband RD, Nelssen JL, Tokach MD, Chengappa MM and 
Blecha F (1996). Influence of lipopolysaccharide-induced immune challenge and 
diet complexity on growth performance and acute-phase protein production in 
segregated early-weaned pigs. J. Anim. Sci. 74: 1620-1628. 
Escobar J, Van Alstine WG, Baker DH and Johnson RW (2004). Decreased protein 
accretion in pigs with viral and bacterial pneumonia is associated with increased 
myostatin expression in muscle. J. Nutr. 134: 3047-3053. 
19 
 
Fan J, Molina PE, Gelato MC and Lang CH (1994). Differential tissue regulation of 
insulin-like growth factor-I content and binding proteins after endotoxin. 
Endocrinology 134: 1685-1692. 
Fernandez AM and LeRoith D (2005). Skeletal Muscle. In: Varela-Nieto I and Chowen 
JA (eds) The growth hormone/insulin-like growth factor axis during development. 
New York: Springer, pp. 117-147. 
Fernandez-Celemin L, Pasko N, Blomart V and Thissen JP (2002). Inhibition of muscle 
insulin-like growth factor I expression by tumor necrosis factor-alpha. Am. J. 
Physio.l Endocrinol.Metab. 283: E1279-E1290. 
Florini JR, Ewton DZ and Coolican SA (1996). Growth hormone and the insulin-like 
growth factor system in myogenesis. Endocr. Rev. 17: 481-517. 
Foulstone EJ, Savage PB, Crown AL, Holly JM and Stewart CE (2003). Role of insulin-
like growth factor binding protein-3 (IGFBP-3) in the differentiation of primary 
human adult skeletal myoblasts. J. Cell Physiol. 195: 70-79. 
Frago LM and Chowen JA (2005). Basic Physiology of the Growth Hormone/Insulin-
Like Growth Factor Axis. In: Varela-Nieto I and Chowen JA (eds) The growth 
hormone/insulin-like growth factor axis during development. New York: 
Springer, pp. 1-25. 
Franchimont N, Durant D and Canalis E (1997). Interleukin-6 and its soluble receptor 
regulate the expression of insulin-like growth factor binding protein-5 in 
osteoblast cultures. Endocrinology 138: 3380-3386. 
Fraser JN, Davis BL, Skjolaas KA, Burkey TE, Dritz SS, Johnson BJ and Minton JE 
(2007). Effects of feeding Salmonella enterica serovar Typhimurium or serovar 
Choleraesuis on growth performance and circulating insulin-like growth factor-I, 
tumor necrosis factor-α, and interleukin-1ß in weaned pigs. J. Anim. Sci 85: 1161-
1167. 
Frost RA and Lang CH (2004). Alteration of somatotropic function by proinflammatory 
cytokines. J. Anim. Sci. 82 E-Suppl: E100-E109. 
Frost RA, Lang CH and Gelato MC (1997). Transient exposure of human myoblasts to 
tumor necrosis factor-alpha inhibits serum and insulin-like growth factor-I 
stimulated protein synthesis. Endocrinology 138: 4153-4159. 
Frost RA, Nystrom GJ and Lang CH (2002). Lipopolysaccharide regulates 
proinflammatory cytokine expression in mouse myoblasts and skeletal muscle. 
Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R698-R709. 
Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G, Ghidoni R and Ghigo E 
(2004). Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: 
involvement of the sphingolipid signaling pathways. FASEB J. 18: 1456-1458. 
20 
 
Hathaway MR, Dayton WR, White ME and Pampusch MS (2003). Effects of 
antimicrobials and weaning on porcine serum insulin-like growth factor binding 
protein levels. J. Anim. Sci. 81: 1456-1463. 
Jenkins NL, Turner JL, Dritz SS, Durham SK and Minton JE (2004). Changes in 
circulating insulin-like growth factor-I, insulin-like growth factor binding 
proteins, and leptin in weaned pigs infected with Salmonella enterica serovar 
Typhimurium. Domest. Anim. Endocrinol. 26: 49-60. 
Johnson BJ, Dritz SS, Skjolaas-Wilson KA, Burkey TA and Minton JE (2005). 
Interactive responses in gut immunity, and systemic and local changes in the 
insulin-like growth factor system in nursery pigs in response to Salmonella 
enterica serovar Typhimurium. J. Anim. Sci. 83:E48-56. 
Johnson RW (1997). Inhibition of growth by pro-inflammatory cytokines: an integrated 
view. J. Anim. Sci. 75: 1244-1255. 
Kelley KW, Kent S and Dantzer R (1993). Why Sick Anim.als Don't Grow: An 
Immunological Explanation. In: Hollis GR (eds) Growth of the pig. Wallingford: 
CAB International, pp. 119-132. 
Lang CH, Krawiec BJ, Huber D, McCoy JM and Frost RA (2006). Sepsis and 
inflammatory insults downregulate IGFBP-5, but not IGFBP-4, in skeletal muscle 
via a TNF-dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 
290: R963-R972. 
Lee CY, Lee HP, Jeong JH, Baik KH, Jin SK, Lee JH and Sohnt SH (2002a). Effects of 
restricted feeding, low-energy diet, and implantation of trenbolone acetate plus 
estradiol on growth, carcass traits, and circulating concentrations of insulin-like 
growth factor (IGF)-I and IGF-binding protein-3 in finishing barrows. J. Anim. 
Sci. 80: 84-93. 
Lee KW and Cohen P (2002b). Nuclear effects: unexpected intracellular actions of 
insulin-like growth factor binding protein-3. J. Endocrinol. 175: 33-40. 
Novakofski J and McCusker RH (1993). Physiology and Principles of Muscle Growth. 
In: Hollis GR (eds) Growth of the pig. Wallingford: CAB International, pp. 33-48. 
Oksbjerg N, Gondret F and Vestergaard M (2004). Basic principles of muscle 
development and growth in meat-producing mammals as affected by the insulin-
like growth factor (IGF) system. Domest. Anim. Endocrinol. 27: 219-240. 
Peng M, Pelletier G, Palin MF, Veronneau S, LeBel D and Abribat T (1996). Ontogeny 
of IGFs and IGFBPs mRNA levels and tissue concentrations in liver, kidney and 
skeletal muscle of pig. Growth Dev. Aging 60: 171-187. 
Roberts CT Jr (2005). The Role of the Insulin-Like Growth Factor System in Pre-and 
Postnatal Growth, Development, and Tumorigenesis. In: Houston MS, Holly JMP 
21 
 
and Feldman EL (eds) IGF and nutrition in health and disease. Totowa, N.J: 
Humana Press, pp. 121-132. 
Sandhu MS (2005). Insulin-Like Growth Factor-I and Risk of Type 2 Diabetes and 
Coronary Heart Disease: Molecular Epidemiology. In: Cianfarani S, Clemmons 
DR and Savage MO (eds) IGF-I and IGF binding proteins 
basic research and clinical management. Basel: Karger, pp. 44-54. 
Scanes CG and Daughaday WH (1995). Growth Hormone Action: Growth. In: Growth 
Hormone. Boca Raton: CRC Press, pp. 351-369. 
Schneider MR, Wolf E, Hoeflich A and Lahm H (2002). IGF-binding protein-5: flexible 
player in the IGF system and effector on its own. J. Endocrinol. 172: 423-440. 
Sheffield-Moore M and Urban RJ (2004). An overview of the endocrinology of skeletal 
muscle. Trends Endocrinol. Metab 15: 110-115. 
Silha JV and Murphy LJ (2005). Insulin-Like Growth Factor Binding Proteins in 
Development. In: Varela-Nieto I and Chowen JA (eds) The growth 
hormone/insulin-like growth factor axis during development. New York: 
Springer, pp. 55-89. 
Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, 
Isaksson OG, Jansson JO and Ohlsson C (1999). Liver-derived insulin-like 
growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required 
for postnatal body growth in mice. Proc. Natl. Acad. Sci. U.S.A 96: 7088-7092. 
Spagnoli A, Longobardi L and O'Rear L (2005). Cartilage Disorders: Potential 
Therapeutic Use of Mesenchymal Stem Cells. In: Cianfarani S, Clemmons DR 
and Savage MO (eds) IGF-I and IGF binding proteins basic research and clinical 
management. Basel: Karger, pp. 17-30. 
Spurlock ME (1997). Regulation of metabolism and growth during immune challenge: an 
overview of cytokine function. J. Anim. Sci. 75: 1773-1783. 
Sunic D, McNeil JD, Rayner TE, Andress DL and Belford DA (1998). Regulation of 
insulin-like growth factor-binding protein-5 by insulin-like growth factor I and 
interleukin-1alpha in ovine articular chondrocytes. Endocrinology 139: 2356-
2362. 
Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL, Klein-Szanto AJ, 
El-Deiry WS, Grimberg A and Nakagawa H (2004). Epidermal growth factor 
receptor regulates aberrant expression of insulin-like growth factor-binding 
protein 3. Cancer Res. 64: 7711-7723. 
Thissen JP (2005). Regulation of Insulin-Like Growth Factor-I by Nutrition. In: Houston 
MS, Holly JMP and Feldman EL (eds) IGF and nutrition in health and disease. 
Totowa, N.J: Humana Press, pp. 25-52. 
22 
 
Wang P, Li N and Li JS (2002a). Mechanism of growth hormone insensitivity induced by 
endotoxin. Acta Pharmacol .Sin. 23: 16-22. 
Wang P, Li N, Li JS and Li WQ (2002b). The role of endotoxin, TNF-alpha, and IL-6 in 
inducing the state of growth hormone insensitivity. World J. Gastroenterol. 8: 
531-536. 
Wang Y, Eleswarapu S, Beal WE, Swecker WS, Jr., Akers RM and Jiang H (2003). 
Reduced serum insulin-like growth factor (IGF) I is associated with reduced liver 
IGF-I mRNA and liver growth hormone receptor mRNA in food-deprived cattle. 
J. Nutr. 133: 2555-2560. 
Webel DM, Finck BN, Baker DH and Johnson RW (1997). Time course of increased 
plasma cytokines, cortisol, and urea nitrogen in pigs following intraperitoneal 
injection of lipopolysaccharide. J. Anim. Sci. 75: 1514-1520. 
Wright KJ, Balaji R, Hill CM, Dritz SS, Knoppel EL and Minton JE (2000). Integrated 
adrenal, somatotropic, and immune responses of growing pigs to treatment with 
lipopolysaccharide. J. Anim. Sci. 78: 1892-1899. 
Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B and LeRoith D (1999). Normal 
growth and development in the absence of hepatic insulin-like growth factor I. 
Proc. Natl. Acad. Sci. U.S.A 96: 7324-7329. 
Zoico E and Roubenoff R (2002). The role of cytokines in regulating protein metabolism 
and muscle function. Nutr. Rev. 60: 39-51. 
23 
 
Chapter 2 
Oral Inoculation with Salmonella enterica serovars Typhimurium or Choleraesuis 
Promotes Divergent Responses in the Somatotropic Growth Axis of Swine 
24 
 
ABSTRACT: Enteric disease and immune challenge are processes that have detrimental 
effects on growth performance of young swine.  The current study tested the hypothesis 
salmonellae-induced enteric disease would perturb the endocrine growth axis in a serovar 
dependent fashion. Specifically, we evaluated effects of Salmonella enterica serovar 
Typhimurium (Typhimurium) and serovar Choleraesuis (Choleraesuis) on critical 
regulatory components of growth in young swine. Weaned pigs were housed 2 per pen 
with ad libitum access to feed and water in a 14 d experiment.  Pigs were then repeatedly 
fed either 108 CFU Choleraesuis or 108 Typhimurium in dough balls, with control pigs 
receiving dough without bacteria.  Bacteria were re-fed twice weekly.  Rectal 
temperatures were monitored daily from d 0 to7 and ADFI was measured through d 14. 
Pigs were weighed and samples of serum were obtained for circulating IGF-I on days 0, 
7, and 14.  At the conclusion of the study, samples of semitendinosus muscle and liver 
were obtained and subsequently assayed for IGF-I, IGFBP-3, and IGFBP-5 mRNA.  
Rectal temperatures were elevated in pigs given Choleraesuis pigs from d 2 through d 7 
(P < 0.05) when compared to control pigs and pigs fed Typhimurium. Pigs receiving 
Choleraesuis had substantially decreased feed intake on days 2, 3, 4, 7, 8, 9, and 10 (P < 
0.01), with a trend for reduction on d 5 (P = .08), and they experienced an approximate 
25% reduction in BW compared to control and Typhimurium pigs by the conclusion of 
the study. Pigs given Choleraesuis also experienced marked reductions in circulating 
IGF-I on d 7 (P < 0.01 vs. control and Typhimurium) with reductions of lesser magnitude 
on d 14 (P = 0.07 vs. control and P < 0.05 vs. Typhimurium). Treatment tended to affect 
liver IGFBP-3 mRNA (P = 0.08), where expression tended to be elevated in 
Typhimurium and Choleraesuis pigs.  In contrast, IGFBP-3 mRNA relative abundance 
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was increased (P < 0.03) in pigs given Typhimurium versus control pigs. Muscle IGF-I 
mRNA was reduced in Choleraesuis pigs compared to control and Typhimurium (P < 
0.05). Treatment tended to affect muscle IGFBP-3 mRNA (P = 0.10), where Choleraesuis 
had numerically less relative abundance than controls.  Oral inoculation of growing pigs 
with Choleraesuis disrupted feed intake and BW gain, and this was accompanied by 
decreases in circulating IGF-I and reduced muscle expression of mRNA for  IGF-I and 
IGFBP-3. 
Keywords: IGF-I, IGFBP-3, IGFBP-5, Salmonella, Swine 
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INTRODUCTION 
 Enteric disease and immune challenge are processes that are generally associated 
with decreased growth in domestic livestock.  In swine, oral infection by Salmonella 
enterica serovar Typhimirium (Typhimurium) results in growth suppression and an array 
of associated physiologic effects (Schwartz, 1999; Balaji et al., 2000; Jenkins et al., 
2004).  Infection by Salmonella enterica serovar Cholerasuis (Choleraesuis), another 
important swine pathogen, is more likely to cause septicemia in growing pigs (Schwartz, 
1999), but little has been reported comparing these two serovars in terms of their effects 
on key regulatory elements of the endocrine growth axis.  We have previously shown that 
infection by Typhimurium results in unmistakable effects on systemic markers of the 
somatotropic growth axis, namely serum IGF-I (Balaji et al., 2000; Burkey et al., 2004) 
and IGFBP-3 in pigs ( Jenkins et al., 2004). In the current study, our objective was to 
directly compare the effects of oral inoculation with Typhimurium and Choleraesuis on 
weaned pigs. Since each serovar produces differing effects on swine, with Typhimurium 
producing mainly self-limiting enteritis, and Choleraesuis, a so-called swine host adapted 
pathogen, being more likely to result in a more serious and occasionally fatal septicemia 
(Schwartz, 1999).  Therefore, we hypothesized that the effects of these two serovars in 
pigs on known promoters of growth in pigs would be differ as well.  
MATERIALS AND METHODS 
Experimental Design.  The experimental protocol used in this study was approved by the 
Kansas State University Institutional Animal Care and Use Committee.  The current 
study reports data from additional tissue collections and measurements made on from a 
study already published (Fraser et al., 2007).  Essential details of that study and others 
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specific to the current report are included here for clarity.  Forty-eight weaned pigs were 
blocked by sex and BW then randomly assigned to 1 of 3 treatments in a 14 d study.  
Each treatment had 8 replicates (pens) containing 2 pigs/pen. In total, 16 pigs served as 
negative controls, 16 pigs were repeatedly fed 108 CFU Typhimurium, and 16 pigs were 
repeatedly fed 108 CFU Choleraesuis.  All pigs received treatments in the form of hand-
fed dough balls.  On d 0, pigs were fed 108 CFU of Choleraesuis or Typhimurium in 
dough balls, with control pigs receiving dough balls without bacteria. Dough balls were 
then re-fed on days 3, 7, and 10 resulting in animals receiving treatment twice weekly 
through the course of the 14 d study.  Details of bacterial culture were described 
previously (Fraser et al., 2007).  All pigs were confirmed to be negative for salmonellae 
organisms by fecal culture prior to inclusion in the study. 
 Pig BWs were recorded on days 0, 7, and 14 and feeders were weighed daily to 
estimate ADFI.  Rectal temperatures were obtained daily from 1 pig/pen (same animal 
each day) from d 0 of the study until 7 d post challenge.  Serum samples were also taken 
from 1 pig/pen (same animal each collection time) on days 0, 7, and 14 to assay for 
circulating IGF-I.  All pigs were humanely euthanized at the conclusion of the study with 
tissue samples of semitendinosus muscle and liver taken for analysis of IGF-I, IGFBP-3 
and IGFBP-5 mRNA expression. All tissue samples were rapidly frozen in liquid 
nitrogen after collection. 
 Serum Analysis.  Serum was collected from a single pig/pen for analysis of 
circulating IGF-I on d 0, 7, and 14.  Serum was subsequently analyzed for circulating 
IGF-I concentrations via an immunoradiometric assay previously described  for use in 
swine (Balaji et al., 2000). 
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 RNA Extraction and Reverse Transcription.  Samples of muscle and liver tissue 
were subjected to total RNA extraction using TRI®-Reagent (Sigma Corporation, St. 
Louis, MO) as per the manufacturer’s protocol.  Following RNA isolation, removal of 
contaminating genomic DNA was performed with the DNA-free™ kit (Ambion Inc., 
Austin TX).  Further quantification of isolated total RNA was done by spectrophotometry 
utilizing an optical density of 260 nm. Quality of total RNA was assessed by 
visualization of the 28S and 18S ribosomal RNA after electrophoresis of samples at 100 
V for 1 hr through 1% agarose-formaldehyde gels with ethidum bromide staining.  
Reverse transcription was performed using Taqman® reverse transcription reagents 
(Applied Biosystems, Foster City, CA) and was conducted in a 50 μL final volume 
consisting of 25mM MgCl2, 500 μM dNTP’s, 2.5μM random hexamers, 0.4 U/μL RNase 
inhibitor, 50 U/μL MultiScribe reverse transcriptase and Taqman RT buffer.  The reverse 
transcription mixture was then incubated at 25°C for 10 min, heated to 37°C for 60 min, 
and inactivated at 95°C for 5 min.  Resultant cDNA was then stored at -80°C until later 
use.  
 Real Time PCR analysis for Gene Expression.  Real-time quantitative PCR was 
used to measure the relative abundance of mRNA for IGF-I, IGFBP-3, IGFBP-5, and 18S 
rRNA in skeletal muscle and hepatic tissues.  The PCR reactions were carried out in 96 
well plates utilizing 900 nM of the appropriate forward and reverse primers along with 
200 nM of the appropriate Taqman detection probe, PCR Mastermix (Applied 
Biosystems, Foster City, CA) and 3.5μL of the cDNA sample.    The porcine specific 
primers and detection probes were synthesized from published GenBank sequences using 
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Primer Express® software (Applied Biosystems, FosterCity, CA) and were identical to 
those published previously (Brown et al., 2007).   
 Statistical Analyses.  Data were analyzed utilizing the PROC MIXED procedure 
in SAS (SAS Inst. Inc., Cary NC).  Data for RT, ADFI, BW, and serum IGF-I 
concentrations were analyzed as a randomized block design with repeated measures over 
time for each experimental unit (pens).  Terms for the fixed effects of disease challenge, 
time, and interactions were included, with block and pen being considered random 
effects.  Muscle and liver mRNA data were also analyzed via a PROC MIXED 
procedure, but without terms for repeated measures and no time statements included in 
the model. All means expressed are least squares means. 
 
RESULTS 
 Rectal temperatures were monitored daily from d 0 through d 7 after the first 
bacterial feeding.  There were no differences in rectal temperatures between control and 
Typhimurium-fed pigs the first 7 d following challenge (Figure 1).  In contrast, pigs 
given Choleraesuis experienced dramatically increased rectal temperature starting on d 2 
and continuing through the end of the monitoring period at d 7 when compared to both 
control and Typhimurium pigs (P < 0.05).  
 Average daily feed intake was measured by weighing feeders for each pen of pigs 
within each treatment daily (Figure 2), and was monitored from d 0 through the 
completion of the study at d 14.  In general, ADFI between control pigs and pigs given 
Typhimurium did not differ.  Conversely, Choleraesuis-challenged pigs had reduced 
ADFI on days 2, 3, 4, 7, 8, 9, and 10 (P < 0.01) and a strong tendency for reduction on d 
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5 (P < 0.08).   Body weights were obtained by weighing pigs on days 0, 7, and 14 
(Figure 3).  Pigs were initially blocked by BW, so as expected, there were no differences 
in BW across treatments at d 0.  However, pigs fed Choleraesuis had reduced BW on d 7 
and 14 compared to control and Typhimurium pigs (P < 0.01).    
Circulating IGF-I concentrations (Figure 4) were not different on d 0 between 
control, Typhimurium and Choleraesuis treatments.  Moreover, serum IGF-I in control 
pigs and pigs receiving Typhimurium treatment remained similar through d 14.  In 
contrast, pigs challenged with Choleraesuis had lower peripheral IGF-I concentrations on 
d 7 when compared to both control pigs and Typhimurium pigs (P < 0.01). In addition, 
Choleraesuis-fed pigs had reductions in serum IGF-I on d 14 when compared to controls 
(P < 0.07) and pigs given Typhimurium (P < 0.05). 
 Relative abundance of mRNA for IGF-I, IGFBP-3, and IGFBP-5 (Figure 5) in 
liver tissue of pigs across all treatments was variable.  Only one treatment difference was 
observed for hepatic tissue with Typhimurium-fed pigs having greater relative abundance 
of IGFBP-3 mRNA compared to control pigs (P < 0.03). However, in the statistical 
model for hepatic IGFBP-3, it should be noted that the main effect of treatment only 
approached significance at P = 0.08. 
 For muscle tissue (Figure 6), pigs challenged with Choleraesuis had reductions in 
IGF-I mRNA expression when compared to control pigs (P < 0.04) and Typhimurium 
pigs (P < 0.002).  In addition, Choleraesuis-fed pigs had reductions in IGFBP-3 mRNA 
expression in skeletal muscle when compared to control pigs (P < 0.03), although the 
overall treatment effect in the statistical model only tended to be significant (P = 0.10).     
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DICUSSION 
 Our laboratory has published findings from weaned pigs challenged with the same 
isolate of Typhimurium used in the current study and have noted its effects on a number 
of variables in pigs including known systemic mediators of growth and development 
(Balaji et al., 2000; Turner et al., 2002a, b; Jenkins et al., 2004).  However, single oral 
dosages used for bacterial challenge were greater in those previous experiments, ranging 
from 109 to 1010 CFU.  In the current experiment, we modified the approach to include an 
isolate of Choleraesuis to compare to Typhimurium and we utilized a lower dose of 
bacteria (108 CFU) but administered it repeatedly. This was done to more closely model 
fecal-oral transmission of salmonellae organisms often found in intense swine 
management and production conditions. In addition, we included repeated exposure to 
Typhimurium and Choleraesuis in an effort to create a model of disease-associated 
growth suppression. 
 In the current study, we tracked rectal temperature, ADFI, and BW as ancillary 
measures to document the course of treatment-induced enteric disease. Clearly, all of 
these measures were affected adversely by repeated oral exposure to Choleraesuis. In 
contrast, none of these measures were affected by repeated exposure to Typhimurium 
(current report and Fraser et al., 2007). Although we expected Typhimurium to disrupt 
ADFI and thereby potentially reduce BW, the oral dose of Typhimurium used in the 
study was low relative to oral doses reported to provoke enteric disease (Schwartz, 1999) 
and relative to those we’ve used previously (Balaji et al., 2000; Turner et al., 2002a,b). 
 We evaluated circulating IGF-I as it is widely accepted that IGF-I can be 
evaluated as a marker of performance and growth (Florini et al., 1996; Oksbjerg et al., 
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2004; Sheffield-Moore and Urban, 2004).  Furthermore, it is established that bacterial 
infection (Balaji et al., 2000) and other non-infectious models of sepsis (Orellana et al., 
2002; Thissen et al., 2005) can lead to decreases in IGF-I in circulation, with these 
decreases often paralleling reductions in feed intake.  In the current study, pigs 
challenged with Typhimurium consistently had circulating IGF-I concentrations that were 
very similar to those of control pigs. Although this contrasts previous findings from our 
group for pigs challenged with Typhimurium (Balaji et al., 2000; Jenkins et al., 2004; 
Turner et al., 2002a,b), the finding is consistent with a lack of Typhimurium effect on 
ADFI in the current study which we think is likely a consequence of the lower dose of 
Typhimurium used here. 
In contrast to pigs receiving Typhimurium, pigs receiving Choleraesuis at this 
same dosage experienced marked reductions in serum IGF-I. This observation is 
consistent with other pathophysiologic effects of Choleraesuis observed in the current 
study, most notably treatment-induced reductions in ADFI.  However, of potentially 
greater significance is our finding that, in addition to circulating IGF-I, pigs challenged 
with Choleraesuis experience reduced steady-state abundance of both muscle mRNA for 
IGF-I and for IGFBP-3. Although decreases in IGF-I mRNA in skeletal muscle have 
been documented after administration of LPS (Fan et al., 1994; Fernandez-Celemin et al., 
2002),  our findings in the current study indicate what we believe to be the first chronic 
disease model that has been documented to disrupt IGF-I and IGFBP-3 locally in skeletal 
muscle.  Our working hypothesis is that these effects are most probably related to the 
lowered feed intakes in pigs challenged with Choleraesuis, as there is a strong body of 
evidence that nutrient intake plays a major role in the regulation and expression of critical 
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mediators of growth (Breier, 1999; Ling and Bistrian, 2005; Thissen et al., 2005). 
Although the effect of Choleraesuis to reduce skeletal muscle mRNA for IGFBP-3 is 
consistent with reduced muscle IGF-I mRNA, we caution that the overall treatment effect 
for IGFBP-3 mRNA only approached significance (P = 0.10). 
Emerging dogma linking disease to mechanisms of reduced growth potential 
suggests that changes in feed intake, often found animals experiencing a disease 
challenge, are manifested by elevated peripheral pro-inflammatory cytokines ( Kelley et 
al., 1993; Johnson, 1997) with TNF-α, IL-1, and IL-6 being predominantly implicated in 
altering metabolism and growth (Spurlock, 1997).  It is of interest to note that in the 
companion study conducted with pen mates of pigs from the current study, Choleraesuis 
challenge was not associated with elevated circulating TNFα or IL-1β (Fraser et al., 
2007). However, it is important to note that local production of inflammatory cytokines, 
not measured in the current study,  may be of greater importance and more reflective of 
local regulation of skeletal muscle growth than systemic cytokines (reviewed in Gabler 
and Spurlock, 2008).   
   Although pigs challenged with repeated oral doses of Choleraesuis pigs 
experienced reductions in IGF-I and IGFBP-3 mRNA in skeletal muscle, these treatment 
effects were not found in hepatic tissue.  In fact the only effect in hepatic tissues was an 
elevation in IGFBP-3 mRNA in pigs fed Typhimurium compared to control pigs, with 
pigs fed Choleraesuis being intermediate between the other treatments. The physiological 
significance of this isolated effect is not readily apparent especially in the context of no 
other treatment effects of repeated Typhimurium feeding at the dose employed in the 
current study. Moreover, the overall treatment effect in the statistical model, like that of 
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muscle IGFBP-3 mRNA, only approached significance (P = 0.08). So, this trend should 
be considered with caution. 
In conclusion, data from the current study document, for the first time in pigs, 
both systemic and local perturbation of the IGF system in skeletal muscle associated with 
Salmonella enterica serovar Choleraesuis-induced disease. Although we expected a priori 
effects of Thyphimurium , at least on systemic IGF-I, the lack of effect of Typhimurium 
at the dose employed in the current study supports our hypothesis of servoar-specific 
effects on growth in pigs. Perhaps these effects reflect the more systemic nature of 
Choleraesuis in contrast to the more enteric nature of Typhimurium. Whether local 
effects on regulation of the muscle IGF system are common to other enteric diseases of 
swine and whether greater doses of Typhimurium would result in similar kinds of 
changes are intriguing questions for future research. 
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Figure 1. Rectal temperatures of pigs orally administered 108 CFU Salmonella enterica 
serovars Typhimurium or Cholerasuis from d 0 through d 7 after challenge. Bacteria were 
fed on d 0, 3, 7, and 10.  Control pigs received dough balls without bacteria.  Asterisks 
indicate days when rectal temperatures in pigs given Choleraesuis were increased relative 
to controls and pigs given Typhimurium (P < 0.05). 
38 
 
 0 1 2 3 4 5 6 7 8 9 10 11 12 13
0.0
0.5
1.0
1.5
2.0
Fe
ed
 In
ta
ke
, k
g/
d
Control
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0.0
0.5
1.0
1.5
2.0
a
a
a
a
Typhimurium
Fe
ed
 In
ta
ke
, k
g/
d
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0.0
0.5
1.0
1.5
2.0
Treatment P < 0.0001
Day P < 0.0001
Trt x Day P < 0.0001
Choleraesuis
Time After First Salmonella Treatment, d
Fe
ed
 In
ta
ke
, k
g/
d
 
Figure 2.  Average daily feed intake of control pigs and pigs orally administered 108 
CFU Salmonella enterica serovars Typhimurium or Cholerasuis. Bacteria were fed on d 
0, 3, 7, and 10.  Control pigs received dough balls without bacteria. Pigs fed Choleraesuis 
experienced reductions in intake on days 2, 3, 4, 7, 8, 9, and 10 (P < 0.01) with a trend 
for reduction on d 5 (P < 0.08) when compared to control pigs. 
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Figure 3.  Body weights of control pigs and pigs orally administered 108 CFU Salmonella 
enterica serovars Typhimurium or Cholerasuis. Bacteria were fed on d 0, 3, 7, and 10.  
Control pigs received dough balls without bacteria.  Pigs receiving Choleraesuis weighed 
less on d 7 and d 14 compared to control and pigs fed Typhimurium (P < 0.01). 
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Figure 4. Serum IGF-I levels in control pigs and pigs orally administered 108 CFU 
Salmonella enterica serovars Typhimurium or Cholerasuis. Bacteria were fed on d 0, 3, 
7, and 10.  Control pigs received dough balls without bacteria.  Bars without common 
superscript within day differ ( a vs. b, P < 0.01); (c vs. e, P < 0.07); (d vs. e, P < 0.05). 
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Figure 5. Expression of IGF-I, IGFBP-3 and IGFBP-5 mRNA in liver tissue of control 
pigs and pigs orally administered 108 CFU Salmonella enterica serovars Typhimurium or 
Cholerasuis. Bacteria were fed on d 0, 3, 7, and 10.  Control pigs received dough balls 
without bacteria. Pigs were sacrificed on d 14. For liver IGFBP-3 mRNA, bars without 
common superscripts differ ( P < 0.03).  
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Figure 6.  Expression of IGF-I, IGFBP-3 and IGFBP-5 in semitendinosus muscle tissue 
of control pigs and pigs orally administered 108 CFU Salmonella enterica serovars 
Typhimurium or Cholerasuis. Bacteria were fed on d 0, 3, 7, and 10.  Control pigs 
received dough balls without bacteria. Pigs were sacrificed on d 14. For muscle IGF-I 
mRNA and IGFBP-3 mRNA, bars without common superscripts differ ( P < 0.05). 
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